

AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method of reducing loss of neurogenesis capacity resulting from neuroinflammation due to cranial irradiation in an individual, the method comprising:

contacting said individual with a dose of a non-steroidal anti-inflammatory drug (NSAID) that crosses the blood-brain barrier, which dose is effective to reduce neuroinflammatory activity by recruitment or activation of monocyte/microglial cells;

wherein said loss of neurogenesis capacity resulting from neuroinflammation due to said cranial irradiation in an individual is reduced.

2. (Canceled)

3. (Previously Presented) The method according to Claim 1, wherein said radiation is ionizing radiation.

4. (Previously Presented) The method according to Claim 1, wherein said contacting is performed prior to said irradiation.

5. (Previously Presented) The method according to Claim 1, wherein said contacting is performed subsequent to said irradiation.

6. (Canceled)

7. (Withdrawn) The method according to Claim 1, wherein said anti-inflammatory agent specifically blocks IL-6 activity.

8. (Withdrawn) The method according to Claim 1, wherein said anti-inflammatory agent blocks MCP-1 activity.

9-13. (Canceled)

14. (Original) The method according to Claim 1, wherein said neurogenesis is central nervous system neurogenesis.

15-20. (Canceled)

21. (Previously Presented) The method according to Claim 1, wherein said non-steroidal anti-inflammatory drug is indomethacin.

Please add the following claim:

22. (New) The method according to Claim 1, wherein said loss of neurogenesis capacity is manifested as a progressive decline in cognition.